| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5344932 | LILLY | N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives |
Jul, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5344932 (Pediatric) | LILLY | N-(pyrrolo(2,3-d)pyrimidin-3-ylacyl)-glutamic acid derivatives |
Jan, 2017
(7 years ago) | |
| US7772209 | LILLY | Antifolate combination therapies |
Nov, 2021
(2 years ago) | |
|
US7772209 (Pediatric) | LILLY | Antifolate combination therapies |
May, 2022
(1 year, 11 months ago) | |
Alimta is owned by Lilly.
Alimta contains Pemetrexed Disodium.
Alimta has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Alimta are:
- US5344932*PED
- US7772209
- US7772209*PED
- US5344932
Alimta was authorised for market use on 07 September, 2007.
Alimta is available in powder;intravenous dosage forms.
Alimta can be used as use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration.
The generics of Alimta are possible to be released after 24 May, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-571) | Sep 26, 2011 |
| New Indication(I-601) | Jul 02, 2012 |
| M(M-122) | Oct 17, 2015 |
| M(M-61) | Mar 17, 2014 |
| Pediatric Exclusivity(PED) | Sep 17, 2014 |
Drugs and Companies using PEMETREXED DISODIUM ingredient
Market Authorisation Date: 07 September, 2007
Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration
Dosage: POWDER;INTRAVENOUS
ALIMTA family patents
